Stage Iiib Gastric Cancer

• CLINICAL_TRIALS trial_result · 2017-12-27
  Clinical Trial Update: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery [Phase 2]

  Phase 2 pilot trial of CRLX101 for advanced/metastatic stomach, gastroesophageal junction, or esophageal cancers that are unresectable; tria…

• CLINICAL_TRIALS trial_result · 2017-12-13
  Clinical Trial Update: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 clinical trial evaluating pralatrexate and oxaliplatin in unresectable or metastatic esophageal, stomach, or gastroesophageal juncti…

• CLINICAL_TRIALS trial_result · 2015-06-03
  Clinical Trial Update: Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach [Phase 2]

  Phase 2 trial evaluating bortezomib with or without irinotecan in gastroesophageal junction and stomach cancers; study completed with result…

• CLINICAL_TRIALS trial_result · 2015-05-01
  Clinical Trial Update: Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma [Phase 2]

  Phase II trial evaluating a triplet regimen of oxaliplatin, irinotecan, and capecitabine in advanced gastric and gastroesophageal junction c…

• CLINICAL_TRIALS trial_result · 2014-01-21
  Clinical Trial Update: Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery [Phase 2]

  A Phase 2 clinical trial evaluated irinotecan hydrochloride with or without alvocidib in advanced stomach and gastroesophageal junction canc…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2013-06-04
  Clinical Trial Update: Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

  This Phase 2 trial evaluated a triplet regimen of irinotecan, cisplatin, and bevacizumab in patients with unresectable or metastatic gastric…